Welcome to our dedicated page for Vivani Medical news (Ticker: $VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vivani Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vivani Medical's position in the market.
Rhea-AI Summary
Vivani Medical, Inc. reports financial results for 2023, focusing on the development of GLP-1 implants for obesity treatment. The company raised $15 million for priority programs, announced positive preclinical data for NPM-115, and disclosed semaglutide as the active ingredient in NPM-139. Vivani is on track to submit new drug applications and anticipates milestones for clinical trials and public offerings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
-
Rhea-AI Summary
Vivani Medical, Inc. appoints industry veteran Daniel Bradbury to its Board of Directors to focus on developing GLP-1 implants for obesity treatment. Bradbury's experience includes leading Amylin Pharmaceuticals to secure approval for Bydureon® in 2012.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
-
Rhea-AI Summary
Vivani Medical, Inc. (Nasdaq: VANI) announces a securities purchase agreement to buy 3,947,368 shares of common stock and warrants in a registered direct offering, expected to generate approximately $15.0 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.78%
Tags
Rhea-AI Summary
Vivani Medical, Inc. (VANI) announces positive preclinical data on NPM-115, a miniature exenatide implant for chronic weight management, showing significant weight loss comparable to semaglutide with twice-yearly dosing. NPM-139, with semaglutide as the active ingredient, offers potential once-yearly dosing. The company aims to prioritize obesity implants for improved health outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
270.3%
Tags
-
Rhea-AI Summary
Vivani Medical, Inc. (Nasdaq: VANI) has announced the addition of NPM-115, a high-dose exenatide implant, to its pipeline, offering a potential alternative to injections or pills for long-term GLP-1 therapy in obese or overweight patients. The company also reported financial results and business updates. Vivani aims to advance its innovative drug implants for chronic diseases, emphasizing NPM-115 for obesity and type 2 diabetes. The company is actively engaged in discussions with the US FDA to initiate LIBERATE-1, the proposed First-In-Human study of NPM-119 in patients with type 2 diabetes, and plans to submit an application for the study in Australia. Vivani's financial results for the third quarter of 2023 indicate a decrease in cash balance but estimated sufficient funds to support operations into early 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.27%
Tags
-
Rhea-AI Summary
Vivani Medical, Inc. to present at BIO Investor Forum and provide updates on its NanoPortal™ implant technology and lead program NPM-119.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
Rhea-AI Summary
Vivani Medical to present at Annual Boulder Peptide Symposium, providing updates on its NanoPortal™ implant technology and lead program NPM-119 for type 2 diabetes and obesity treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
-
Rhea-AI Summary
Vivani Medical's subsidiary, Cortigent, to present 5-year clinical trial results for Orion Visual Cortical Prosthesis System at research congress, showing no device malfunctions and potential for meaningful visual perception for blind individuals. Study extended to six years for further assessment. Positive potential for future pivotal study and FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
-
Rhea-AI Summary
Vivani Medical reports Q2 financial results and business update. The company has completed the production of clinical trial materials and submitted an IND application for its lead therapeutic candidate, NPM-119. The FDA has placed the IND on clinical hold, but Vivani intends to respond and proceed with its Phase 2 clinical study. Vivani expects to commence enrollment in the study in the second half of 2023, with interim data available in H1 2024 and full results in H2 2024. The company also plans to move its headquarters to a new facility in Alameda, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.66%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
Vivani Medical, Inc.
Nasdaq:VANI
VANI Rankings
VANI Stock Data
93.46M
30.66M
45.57%
6.29%
1.58%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
ALAMEDA
About VANI
vivani leverages proprietary technologies to develop and commercialize drug and device implants, including its lead asset npm-119 (exenatide implant), which seeks to treat patients with chronic diseases with high unmet medical need.